Severe haemophilia A with haemarthrosis improved on emicizumab: A case report

1. Kaneda M, Kawasaki R, Matsumoto N, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost 2021; 19: 2938–46. doi: 10.1111/jth.15506. KanedaM KawasakiR MatsumotoN Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A J Thromb Haemost 2021 19 2938 46 10.1111/jth.15506 Open DOISearch in Google Scholar

2. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011; 37: 737–44. doi: 10.1055/s-0031-1297164. KulkarniR SoucieJM Pediatric hemophilia: a review Semin Thromb Hemost 2011 37 737 44 10.1055/s-0031-1297164 Open DOISearch in Google Scholar

3. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47. doi: 10.1111/j.1365-2516.2012.02909.x. SrivastavaA BrewerAK Mauser-BunschotenEP Guidelines for the management of hemophilia Haemophilia 2013 19 e1 47 10.1111/j.1365-2516.2012.02909.x Open DOISearch in Google Scholar

4. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447–56. doi: 10.1016/S0140-6736(11)61139-2. BerntorpE ShapiroAD Modern haemophilia care Lancet 2012 379 1447 56 10.1016/S0140-6736(11)61139-2 Open DOISearch in Google Scholar

5. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12 Suppl 3: 117–21. doi: 10.1111/j.1365-2516.2006.01268.x. RoosendaalG LafeberFP Pathogenesis of haemophilic arthropathy Haemophilia 2006 12 Suppl 3 117 21 10.1111/j.1365-2516.2006.01268.x Open DOISearch in Google Scholar

6. Kuijlaars I a. R, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: Factors associated with deterioration. Haemophilia 2017; 23: 934–40. doi: 10.1111/hae.13327. KuijlaarsI a. R TimmerMA de KleijnP PistersMF FischerK Monitoring joint health in haemophilia: Factors associated with deterioration Haemophilia 2017 23 934 40 10.1111/hae.13327 Open DOISearch in Google Scholar

7. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4: 59–72. doi: 10.1177/2040620712464509. WitmerC YoungG Factor VIII inhibitors in hemophilia A: rationale and latest evidence Ther Adv Hematol 2013 4 59 72 10.1177/2040620712464509 Open DOISearch in Google Scholar

8. Blair HA. Emicizumab: A review in haemophilia A. Drugs 2019; 79: 1697–707. doi: 10.1007/s40265-019-01200-2. BlairHA Emicizumab: A review in haemophilia A Drugs 2019 79 1697 707 10.1007/s40265-019-01200-2 Open DOISearch in Google Scholar

9. US Food and Drug Administration. FDA approves emicizumabkxwh for hemophilia A with or without factor VIII inhibitors. 2019. Available from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwhhemophilia-or-without-factor-viii-inhibitors (accessed 12 November 2022). US Food and Drug Administration FDA approves emicizumabkxwh for hemophilia A with or without factor VIII inhibitors 2019 Available from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwhhemophilia-or-without-factor-viii-inhibitors (accessed 12 November 2022). Search in Google Scholar

10. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134: 2127–38. doi: 10.1182/blood.2019001869. YoungG LiesnerR ChangT A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Blood 2019 134 2127 38 10.1182/blood.2019001869 Open DOISearch in Google Scholar

11. Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25: 979–87. doi: 10.1111/hae.13848. ShimaM NogamiK NagamiS A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors Haemophilia 2019 25 979 87 10.1111/hae.13848 Open DOISearch in Google Scholar

12. Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia 2020; 26: 1009–18. doi: 10.1111/hae.14183. MancusoME MahlanguJ SidonioR Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study Haemophilia 2020 26 1009 18 10.1111/hae.14183 Open DOISearch in Google Scholar

13. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorbidity 2011; 1: 51–9. doi: 10.15256/joc.2011.1.2. KnobeK BerntorpE Haemophilia and joint disease: pathophysiology, evaluation, and management J Comorbidity 2011 1 51 9 10.15256/joc.2011.1.2 Open DOISearch in Google Scholar

14. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136: 777–87. doi: 10.1111/j.1365-2141.2007.06490.x. RaffiniL MannoC Modern management of haemophilic arthropathy Br J Haematol 2007 136 777 87 10.1111/j.1365-2141.2007.06490.x Open DOISearch in Google Scholar

15. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44. doi: 10.1056/NEJMoa067659. Manco-JohnsonMJ AbshireTC ShapiroAD Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia N Engl J Med 2007 357 535 44 10.1056/NEJMoa067659 Open DOISearch in Google Scholar

16. Khawaji M, Astermark J, Akesson K, Berntorp E. Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis. Blood Coagul Fibrinolysis 2011; 22: 50–5. doi: 10.1097/MBC.0b013e32834128c6. KhawajiM AstermarkJ AkessonK BerntorpE Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis Blood Coagul Fibrinolysis 2011 22 50 5 10.1097/MBC.0b013e32834128c6 Open DOISearch in Google Scholar

17. Coppola A, Di Capua M, De Simone C. Primary prophylaxis in children with haemophilia. Blood Transfus 2008; 6 Suppl 2:s 4–11. doi: 10.2450/2008.0030-08. CoppolaA Di CapuaM De SimoneC Primary prophylaxis in children with haemophilia Blood Transfus 2008 6 Suppl 2 s 4 11 10.2450/2008.0030-08 Open DOISearch in Google Scholar

18. Mauser-Bunschoten EP, Fransen Van De Putte DE, Schutgens REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853–63. doi: 10.1111/j.1365-2516.2009.01987.x. Mauser-BunschotenEP Fransen Van De PutteDE SchutgensREG Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy Haemophilia 2009 15 853 63 10.1111/j.1365-2516.2009.01987.x Open DOISearch in Google Scholar

19. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467–73. doi: 10.1182/blood-2003-05-1457. SoucieJM CianfriniC JancoRL Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors Blood 2004 103 2467 73 10.1182/blood-2003-05-1457 Open DOISearch in Google Scholar

20. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105: 545–53. doi: 10.3324/haematol.2019.232132. MannucciPM Hemophilia therapy: the future has begun Haematologica 2020 105 545 53 10.3324/haematol.2019.232132 Open DOISearch in Google Scholar

21. Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Emicizumab for hemophilia A without inhibitors. Expert Rev Hematol 2019; 12: 515–24. doi: 10.1080/17474086.2019.1624519. CafuirL Kruse-JarresR MancusoME KemptonCL Emicizumab for hemophilia A without inhibitors Expert Rev Hematol 2019 12 515 24 10.1080/17474086.2019.1624519 Open DOISearch in Google Scholar

22. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809–18. doi: 10.1056/NEJMoa1703068. OldenburgJ MahlanguJN KimB Emicizumab prophylaxis in hemophilia A with inhibitors N Engl J Med 2017 377 809 18 10.1056/NEJMoa1703068 Open DOISearch in Google Scholar

23. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379: 811–22. doi: 10.1056/NEJMoa1803550. MahlanguJ OldenburgJ Paz-PrielI Emicizumab prophylaxis in patients who have hemophilia A without inhibitors N Engl J Med 2018 379 811 22 10.1056/NEJMoa1803550 Open DOISearch in Google Scholar

24. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6: e295–305. doi: 10.1016/S2352-3026(19)30054-7. PipeSW ShimaM LehleM Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study Lancet Haematol 2019 6 e295 305 10.1016/S2352-3026(19)30054-7 Open DOISearch in Google Scholar

25. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies. Blood 2021; 137: 2231–42. doi: 10.1182/blood.2020009217. CallaghanMU NegrierC Paz-PrielI Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies Blood 2021 137 2231 42 10.1182/blood.2020009217 Open DOISearch in Google Scholar

26. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 Open DOISearch in Google Scholar